Cargando…
Development of therapeutic antibodies for the treatment of diseases
Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in 1986, 165 antibody drugs have been approved or are under regulatory review worldwide. With the approval of new drugs for treating a wide range of diseases, including cancer and autoimmune and metabolic disorders,...
Autores principales: | Wang, Zeng, Wang, Guoqing, Lu, Huaqing, Li, Hongjian, Tang, Mei, Tong, Aiping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684400/ https://www.ncbi.nlm.nih.gov/pubmed/36418786 http://dx.doi.org/10.1186/s43556-022-00100-4 |
Ejemplares similares
-
Development of therapeutic antibodies for the treatment of diseases
por: Lu, Ruei-Min, et al.
Publicado: (2020) -
Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities
por: Wang, Guoqing, et al.
Publicado: (2022) -
Immunotherapy of glioblastoma: Recent advances and future prospects
por: Yuan, Boyang, et al.
Publicado: (2022) -
Combination therapeutics in complex diseases
por: He, Bing, et al.
Publicado: (2016) -
MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
por: Li, Hongjian, et al.
Publicado: (2020)